The U.S. FDA and drug manufacturer Biogen Idec have issued a drug safety alert advising physicians that Zevalin can be associated with severe cutaneous or mucocutaneous reactions, some of which have been fatal. The Zevalin therapeutic regimen combines the anti-CD20 monoclonal antibodies Zevalin and Rituxan with indium-111- and yttrium-90 labeled radioisotopes. The regimen is indicated for the treatment of patients with specific types of non-Hodgkin's lymphoma.

Rituximab is an essential component of the Zevalin therapeutic regimen. Deaths have occurred within 24 hours of rituximab infusion and approximately 80% of fatal infusion reactions occurred in association with the first rituximab infusion. The fatalities were associated with, "an infusion reaction symptom complex that included hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock."

Other reported side effects of Zevalin include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, and exfoliative dermatitis.

Register your Zevalin Complaint

If a loved one has died after being infused with Zevalin, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please fill in our form on the right to submit your complaint and we will have a lawyer review your Zevalin complaint.

At, it is our goal to keep you informed about important legal cases and settlements. We are dedicated to helping you resolve your legal complaints.

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help